¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"low malignant potential tumor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
¿µ¹® malignant tumor ÇÑ±Û ¾Ç¼ºÁ¾¾ç
¼³¸í   
  Á¤»óÀûÀΠÁ¶Á÷ ¼¼Æ÷°¡ °¢Á¾ ¹°¸®Àû-È­ÇÐÀû-»ý¹°ÇÐÀûÀΠ¹ß¾Ï ¹°ÁúÀÇ Àۿ렶Ǵ ¿äÀο¡ ÀÇÇØ µ¹¿¬º¯À̸¦ ÀÏÀ¸ÄѼ­ Çü¼ºµÇ´Â Á¾¾ç. ¹«Á¦ÇÑÀÇ ¼¼Æ÷ºÐ¿­·Î ¸Å¿ì ¿Õ¼ºÇϰԠÁõ½ÄÇÏ¿© ÁÖÀ§Á¶Á÷À» ÆÄ±«-ħ½ÄÇÑ´Ù. ¶Ç ¾î¶² È­Çй°ÁúÀ» ³»¾î ÁÖÀ§ÀÇ Á¶Á÷¼¼Æ÷¸¦ Ä§ÇØÇÒ »Ó¸¸ ¾Æ´Ï¶ó, Ç÷°ü ¹× ¸²ÇÁ°üÀ» µû¶ó ÀüÀÌÇÏ¿© Àü½ÅÀÇ Ä«ÄʽþƸ¦ÀÏÀ¸ÄÑ Á×À½À» ÃÊ·¡ÇÑ´Ù. »óÇǼºÀΠ°ÍÀ» ¾ÏÁ¾À̶ó Çϰí, ºñ»óÇǼºÀΠ°ÍÀ» À°Á¾À̶ó ÇÑ´Ù.
¿µ¹® malignant melanoma ÇÑ±Û ¾Ç¼ºÈæ»öÁ¾
¼³¸í   
  ÇǺο¡¼­ »ý±â´Â ¾ÏÀÇ ÀÏÁ¾. ÁַΠ¹éÀο¡°Ô È£¹ßÇϸç, 50´ë~70´ë¿¡ ¸¹ÀÌ ¹ß»ýÇϰí, ÀþÀº ¿©¼º¿¡°Ô Áõ°¡Çϴ °æÇâÀÌ ÀÖÀ¸¸ç, ÇǺξÏÁß 1~3%¸¦ Â÷ÁöÇϴ µå¹® º´À¸·Î ÇǺο͠±âŸ ±â°üÀÇ ¸á¶ó´Ñ ¼¼Æ÷°è¿¡¼­ À¯·¡Çϴ ¾Ç¼ºÁ¾¾çÀÌ´Ù.
  
  ¿øÀÎÀ¸·Î Àϱ¤³ëÃâ°ú Á÷Á¢ÀûÀΠ°ü°è°¡ ÀÖÀ¸¸ç °¡Á·Àû ¹ß»ýµµ º¼ ¼ö ÀÖ´Ù.
¿µ¹® solid tumor ÇÑ±Û °íÇüÁ¾¾ç
¼³¸í   
  ¼¼Æ÷·Î ²Ë Âù Á¾¾çÀ» ¸»ÇÔ. ¹éÇ÷º´ µîÀÇ Ç÷¾×¾Ï°ú °°ÀÌ ÇüŸ¦ ÃëÇÏÁö ¾Ê°í ¾×üÀΠ»óÅÂÀÇ ¾Ï°ú ´ëÁ¶µÇ´Â ¿ë¾î·Î¼­ ´Ü´ÜÇÑ µ¢¾î¸®·Î ±¸¼ºµÈ ¾Ç¼ºÁ¾¾çÀÌ´Ù. ´ëºÎºÐÀÇ Á¾¾çÀÌ ÀÌ¿¡ ÇØ´çÇÑ´Ù. Æ¯È÷ Ç¥ÇÇÁ¶Á÷¿¡¼­ ±â¿øÇÑ Á¾¾çÀ» ¸»ÇÑ´Ù.
¿µ¹® ulcerating tumor ÇÑ±Û ±Ë¾ç¼º Á¾¾ç
¼³¸í   
  Á¾¾çÀǠǥ¸é¿¡ ±Ë¾çÀÌ ¹ß»ýÇϴ °Í. ´ë°³, ¸Å¿ì »¡¸® ÀÚ¶ó´Â Á¾¾ç¿¡¼­ Ç÷·ù °ø±ÞÀÌ Á¾¾ç¼¼Æ÷ÀÇ ÀÚ¶ó´Â ¼Óµµ¸¦ °¨´çÇÏÁö ¸øÇØ Á¾¾çÁ߽ɺΠÁ¶Á÷ÀÌ ±«»ç¿¡ ºüÁ® ±Ë¾çÀ» Çü¼ºÇϴ °æ¿ì°¡ ¸¹´Ù. À°¾ÈÀ¸·Î º¸¸é »¡°²°í, ¿­À̳ª¸ç, ÁöÀúºÐÇØ º¸ÀδÙ.
¿µ¹® brain tumor ÇÑ±Û ³úÁ¾¾ç
¼³¸í   
  ³úÁ¾¾çÀ̶õ ³ú¿Í ³úÁ¶Á÷¿¡¼­ »ý±ä Á¾¾çÀ» ÁöĪÇϴ ¸»ÀÌ´Ù. ±×·¯³ª ´ë°³ ³ÐÀº Àǹ̷Π»ç¿ëÇÒ °æ¿ì¿¡´Â ¸Ó¸®»À¼ÓÀÇ °ø°£ÀΠµÎ°³°­¼Ó¿¡ »ý±â´Â ¸ðµç Á¾¾çÀ» À̸£´Â ¸»·Î »ç¿ëµÈ´Ù.
  
  ³úÁ¾¾çÀº ÇÑÁ¤µÈ °ø°£ÀΠµÎ°³°­¿¡¼­ ¹ß»ýÇϹǷΠÁ¾¾çÀÌ ±×´ÙÁö Å©Áö ¾Ê¾Æµµ Á¤»óÀûÀΠÁ¶Á÷À» ¾Ð¹ÚÇϰԠµÇ°í, µÎ°³°­³»ÀÇ ¾Ð·ÂÀ» ³ôÀδÙ. ÀÌ·± Æ¯Â¡¿¡ ÀÇÇØ¼­ ³úÁ¾¾çÀÇ Áõ»óÀº ´Ù¸¥ Á¾¾ç°ú ´Þ¸®, Á¾¾ç ±× ÀÚüÀÇ Áõ»óº¸´Ùµµ µÎ°³³»¾Ð»ó½Â°ú Á¤»óÁ¶Á÷ÀÇ ¾Ð¹Ú¿¡ ÀÇÇÑ Áõ»óÀÌ ¸¹´Ù. µÎ°³³»¾Ð(³ú¾Ð)ÀÇ »ó½Â¿¡ ÀÇÇÑ Áõ»óÀ¸·Î´Â µÎÅë, ±¸ÅäµîÀÌ ÀÖÀ¸¸ç, Áö¼ÓÀûÀΠ³ú¾Ð»ó½Â¿¡ ÀÇÇØ¼­ À¯µÎºÎÁ¾(papilledema)ÀÌ °üÂûµÇ±âµµ ÇÑ´Ù. ±×¸®°í Á¤»óÀûÀΠ³úÁ¶Á÷ÀÇ ¾Ð¹Ú°ú Á¾¾çÀÌ »ý±ä ºÎÀ§ÀÇ ±â´ÉÀÇ °áÇÕ¿¡ ³úÀÇ ±× ºÎºÐ¿¡ ÇØ´çÇϴ ±â´ÉÀÇ »ó½ÇÀ» º¸°ÔµÈ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • malignant tumor
    ¾Ç¼ºÁ¾¾ç
  • choroidal malignant melanoma
    ¸Æ¶ô¸·¾Ç¼ºÈæ»öÁ¾
  • malignant
    ¾Ç¼º-
  • malignant anemia
    ¾Ç¼ººóÇ÷
  • malignant carcinoid
    ¾Ç¼ºÄ«¸£½Ã³ëÀ̵å, ¾Ç¼ºÀ¯¾ÏÁ¾
  • malignant change
    ¾Ç¼ºº¯È­
  • malignant cholera
    ¾Ç¼ºÄÝ·¹¶ó
  • malignant degeneration
    ¾Ç¼ºº¯¼º
  • malignant fibrous histiocytoma
    ¾Ç¼º¼¶À¯Á¶Á÷±¸Á¾
  • malignant hidradenoma
    ¾Ç¼º¶¡»ùÁ¾
  • malignant hypertension
    ¾Ç¼º°íÇ÷¾Ð
  • malignant hyperthermia
    ¾Ç¼º°í¿­
  • malignant melanoma
    ¾Ç¼ºÈæ»öÁ¾
  • malignant mesothelioma
    ¾Ç¼ºÁßÇÇÁ¾
  • malignant myopia
    ¾Ç¼º±Ù½Ã
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • malignant tumor
    ¾Ç¼ºÁ¾¾ç
  • sex cord-stromal tumor tumor
    ¼º²ö°£ÁúÁ¾¾ç, ³­¼Ò¹öÆÀÁúÁ¾¾ç
  • low fever
    ¹Ì¿­
  • low risk group
    ÀúÀ§Ç豺
  • low density lipoprotein
    Àú¹ÐµµÁöÁú´Ü¹é
  • very low density lipoprotein
    ÃÊÀú¹ÐµµÁöÁú´Ü¹é
  • malignant
    ¾Ç¼º-
  • malignant mesothelioma
    ¾Ç¼ºÁßÇÇÁ¾
  • malignant melanoma
    ¾Ç¼ºÈæ»öÁ¾
  • low potency
    ÀúÈ¿´É, Àú¿ª°¡, ÀúÀáÀç·Â
  • low signal
    ¾àÇѽÅÈ£, Àú½ÅÈ£
  • neuroleptic malignant syndrome
    Ç×Á¤½Åº´¾à¹°¾Ç¼ºÁõÈıº
  • malignant transformation
    ¾Ç¼º¼¼Æ÷Àüȯ
  • potential difference
    Àü¾ÐÂ÷, ÀüÀ§Â÷
  • potential gradient
    ÀüÀ§±â¿ï±â, ÀüÀ§Â÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • malignant tumor
    ¾Ç¼ºÁ¾¾ç
  • malignant anemia
    (¢¡pernicious anemia) ¾Ç¼ººóÇ÷
  • borderline malignant epithelial ovarian neoplasm
    °æ°è¾Ç¼º»óÇdz­¼ÒÁ¾¾ç
  • malignant carcinoid
    ¾Ç¼ºÄ«¸£½Ã³ëÀ̵å, ¾Ç¼ºÀ¯¾ÏÁ¾
  • malignant change
    ¾Ç¼ºº¯È­
  • malignant cholera
    ¾Ç¼ºÄÝ·¹¶ó
  • malignant degeneration
    ¾Ç¼ºº¯¼º
  • malignant reticulemic erythroderma
    ¾Ç¼º¸Á»óÈ«»öÇǺÎÁõ
  • malignant hidradenoma
    ¾Ç¼º¶¡»ùÁ¾
  • malignant hypertension
    ¾Ç¼º°íÇ÷¾Ð
  • malignant hyperthermia
    ¾Ç¼º°í¿­
  • malignant fibrous histiocytoma
    ¾Ç¼º¼¶À¯Á¶Á÷±¸Á¾
  • malignant progressive histiocytoma
    ¾Ç¼ºÁøÇàÁ¶Á÷±¸Á¾
  • malignant
    ¾Ç¼º-
  • malignant acanthosis nigricans
    ¾Ç¼ºÈæ»ö°¡½Ã¼¼Æ÷Áõ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Castellani-Low symptom
    Ä«½ºÅÚ¶ó´Ï-·Î¿ìÁõ»ó.
  • LDL = low density lipoprotein
    Àú¹ÐµµÁö´Ü¹é(î¸ÚËÓøò·Ó±ÛÜ)
  • VLDL => very low density lipoprotein
    ÃÊÀú¹ÐµµÁö ´Ü¹éÁú
  • frequency deafness, low
    ÀúÁ֯ijó, ÀúÁÖÆÄ±Í¸ÔÀ½
  • hellp(hemolysis, elevated liver enzymes, low platelet),heliminths
    À±Ãæ(ëÌõù)
  • Hodgkin s disease =malignant lymphoma
    È£ÁîŲº´.
  • Hodgkin s disease =malignant lymphoma
    È£ÁîŲº´.
  • granuloma, malignant
    ¾Ç¼ºÀ°¾ÆÁ¾
  • histiocytoma,malignant fibrous
    Á¶Á÷±¸Á¾, ¾Ç¼º ¼¶À¯¼º
  • histiocytosis,malignant
    ¾Ç¼º
  • hypertension,malignant
    ¾Ç¼º(äÂàõ)
  • EP =endocochlear potential
    ¿Í¿ì³»(Á÷·ù)ÀüÀ§
  • EPSP (excitatory postsynaptic potential)
    ÈïºÐ¼º(ýéÝÇàõ)½Ã³³½ºÈÄ(ý­)ÀüÀ§(ï³êÈ), ÈïºÐ¼º ¿¬Á¢(Ö§ïÈ)ÀüÀ§
  • Generator potential
    ±âµ¿ÀüÀ§(ÑÃÔÑï³êÈ)
  • IPSP = inhibitory postsynaptic potential
    ¾ïÁ¦¼º(åäð¤àõ)½Ã³À½ºÈÄ(ý­)Àü¾Ð(ï³äâ)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • jaw,nonodontogenic malignant tumor
    ºñÄ¡¾Æ¼º ¾Ç¼ºÁ¾¾ç (¡­ äÂàõðþåË)
  • malignant carcinoid tumor
    ¾Ç¼ºÄ«¸£½Ã³ëÀ̵åÁ¾¾ç(¡­ðþåË).
  • malignant peripheral nerve sheath tumor
    ¾Ç¼º¸»ÃʽŰæÃÊÁ¾¾ç(¡­ØÇôþãêÌèõ¨ðþåË)
  • malignant tumor
    ¾Ç¼ºÁ¾¾ç(¡­ðþåË).
  • malignant tumor
    ¾Ç¼ºÁ¾¾ç(¡­ðþåË)
  • potential tumor doubling time
    ÀáÀçÁ¾¾ç¹è°¡½Ã°£
  • brain tumor =cerebral tumor
    ½Å ¿Ü ³úÁ¾¾ç(ÒàðþåË).
  • superior sulcus tumor(carcinoma)=pancoast tumor
    »ó±¸¾ÏÁ¾
  • trichilemmal tumor => pilar tumor
  • tumor albus =white tumor ³ª
    ¹éÁ¾(ÛÜðþ)
  • autoimmune disease,bypass of t-helper cell(low zone)
    T-º¸Á¶¼¼Æ÷ ³»¼º ¿ìȸ(¡­ÜÍð¾á¬øàÒ±àõéæüß)
  • continuous low dose rate irradiation
    Àú¼±·®À²¿¬¼Ó¹æ»ç¼±Á¶»ç
  • ear, low set
    ÀúÀ§ÀÌ
  • fast Low Angle Shot(FLASH)
    °í¼Ó Àú°¢ ¿µ»ó ȹµæ
  • frequency deafness, low
    ÀúÁ֯ijó, ÀúÁÖÆÄ±Í¸ÔÀ½
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Deficiency (Monstrous tumor)
    °áÇÌ (±«¹°Á¾)
    [¿¾ ¿ë¾î] °áÇÌ
  • Monstrous tumor
    ±«¹°Á¾
    [¿¾ ¿ë¾î] ±«¹°Á¾
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • low-potential iron protein
    ÀúÀüÀ§ ö´Ü¹éÁú(î¸ï³êÈôÑÓ±ÛÜòõ)
  • ectopic tumor
    ÀÌ¼Ò Á¾¾ç(ì¶á¶ðþåË)
  • Ehrlich ascites tumor
    ¿¡¸¦¸®È÷ º¹¼öÁ¾(ÜÙâ©ðþ)
  • primary tumor
    ¿ø¹ß¼º Á¾¾ç(ê«Û¡àõðþåË)
  • tumor angiogenesis facotr
    Á¾¾ç Ç÷°üÇü¼ºÀÎÀÚ(ðþåËúìηû¡à÷ì×í­)
  • tumor antigen
    Á¾¾çÇ׿ø(ðþåËù÷ê«)
  • tumor initiator
    Á¾¾ç °³½ÃÀÚ(ðþåËËÒã·í­)
  • tumor necrosis factor
    Á¾¾ç ±«»çÀÎÀÚ(ðþåËÎÕÞÝì×í­)
  • tumor progression
    Á¾¾çÁøÇà(ðþåËòäú¼)
  • tumor promoter
    Á¾¾çÃËÁøÀÚ(ðþåËõµòäí­)
  • tumor-specific transplantation antigen
    Á¾¾çƯÀÌ ÀÌ½Ä Ç׿ø(ðþåË÷åì¶ì¹ãÕù÷ê«)
  • tumor virus
    Á¾¾ç(ðþåË)¹ÙÀÌ·¯½º
  • low-angle x-ray diffraction
    ¼Ò°¢(á³ÊÇ) X-¼±È¸Àý(àÊüÞï¹)
  • low background counter
    ³·Àº¹ÙÅÁ °è¼ö±â(ͪâ¦Ðï)
  • low-copy number
    Àú(î¸)Ä«ÇǼö(â¦)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • malignant tumor
    ¾Ç¼ºÁ¾¾ç
  • complex potential
    º¹ÇÕÀüÀ§
  • electrical potential
    ˟ˤ
  • electrostatic potential
    Á¤Àü±âÀü·ù
  • evoked potential
    À¯¹ßÀüÀ§
  • magnetic potential
    ÀÚ±âÆ÷ÅÙ¼È
  • fast Low Angle Shot [=FLASH]
    °í¼ÓÀú°¢¿µ»óȹµæ
  • low attenuation
    ³·Àº °¨¾à
  • low back pain
    ¿äÅë
  • low echo area
    Àú¿¡ÄÚ±¸¿ª
  • low field MR scanner
    ÀúÀÚÀåÀÚ±â°ø¸í½ºÄ³³Ê
  • low intensity void in proton flow
    ¾ç¼ºÀÚÈ帧ÀÇ Àú°­µµ¼Ò½Ç
  • low pass filter
    ÀúÅë°ú¿©°ú±â
  • low signal
    Àú½ÅÈ£
  • low signal intensity
    Àú½ÅÈ£°­µµ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
MH malignant histiocytosis; malignant hyperpyrexia; malignant hypertension; malignant hyperthermia; mam...
MAP malignant atrophic papulosis; mandibular angle plane; maturation-activated protein; maximal aerobic ...
MHS major histocompatibility system; malignant hyperthermia in swine; malignant hyperthermia syndrome; m...
LP labile peptide; labile protein; laboratory procedure; lactic peroxidase; lamina propria; laryngophar...
SEP self-evaluation process; sensory-evoked potential; septum; somatosensory evoked potential; sperm ent...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
LMP Low Malignant Potential
MMMT Malignant Mixed Mesodermal Tumor
MMMT Malignant mixed Mullerian tumor
MRT Malignant rhabdoid tumor
CMM Cutaneous malignant melanoma
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • low biscuit stage µµÀç ÀÔÀÚ°¡ ¼­·Î ÀÀÁýµÇ³ª ´Ù°ø¼ºÀ̸ç, ºÎ¼­Áö±â ½¬¿î »óÅÂ.

    low blood pressure

    ÀúÇ÷¾Ð
    Ç÷¾Ð°è·Î Àü¿Ï µ¿¸ÆÀÇ Ç÷¾ÐÀ» ÃøÁ¤ÇÏ¿´À» ¶§ Ç÷¾ÐÀÌ Á¤»óº¸´Ù ³·Àº °æ¿ìÀÇ ÃÑĪ. Á¤»ó °ªÀº ¿¬·É, ¼º¿¡ µû¶ó ´Ù¸£Áö¸¸, ´ë°³ ÃÖ°í Ç÷¾ÐÀÌ 100 mmHg ÀÌÇÏÀ̸é ÀúÇ÷¾ÐÀ̶ó°í ÇÑ´Ù. ±×·¯³ª °íÇ÷¾ÐÁõÀÇ »ç¶÷ÀÌ ±Þ°ÝÈ÷ Ç÷¾ÐÀÌ ¶³¾îÁø °æ¿ì´Â Ç÷¾ÐÄ¡°¡ ºñ·Ï Á¤»ó ¹üÀ§¶ó ÇÒÁö¶óµµ ÀúÇ÷¾Ð Áõ¼¼¸¦ ÃÊ·¡ÇÏ´Â ¼ö°¡ ÀÖ´Ù. ÀúÇ÷¾ÐÀ» ÃÊ·¡ÇÏ´Â ÁúȯÀ¸·Î¼­´Â Å©°Ô ¸¸¼º Áö¼Ó¼º ÀúÇ÷¾ÐÁõ°ú ±â¸³¼º ÀúÇ÷¾Ð ¹× ¼îÅ©°¡ ÀÖ´Ù.¡¼¸¸¼º Áö¼Ó¼º ÀúÇ÷¾ÐÁõ¡½ °¢Á¾ÀÇ ½É Áúȯ
  • low-voltage low-amperage biphasic current
    ÀúÀü¾Ð ÀúÀü·ùÀÇ º¹Çü Àü·ù
  • low-voltage, low-amperage, biphasic current
    ÀúÀü¾Ð ÀúÀü·ùÀÇ º¹Çü Àü·ù
  • jaw,nonodontogenic malignant tumor
    ºñÄ¡¾Æ¼º ¾Ç¼º Á¾¾ç
  • malignant carcinoid tumor
    ¾Ç¼º Ä«¸£½Ã³ëÀ̵å Á¾¾ç
  • malignant salivary gland tumor
    ¾Ç¼º Ÿ¾×¼± Á¾¾ç
  • malignant tumor
    ¾Ç¼º Á¾¾ç
    Á¤»óÀûÀÎ Á¶Á÷ ¼¼Æ÷°¡ °¢Á¾ ¹°¸®Àû, È­ÇÐÀû, »ý¹°ÇÐÀûÀÎ ¾Ï¿ø¼º ¹°ÁúÀÇ ÀÛ¿ë ¶Ç´Â ¿äÀο¡ ÀÇÇØ µ¹¿¬º¯À̸¦ ÀÏÀ¸ÄѼ­ Çü¼ºµÇ´Â Á¾¾ç ¹«Á¦ÇÑÀÇ ¼¼Æ÷ ºÐ¿­·Î ¸Å¿ì ¿Õ¼ºÇÏ°Ô Áõ½ÄÇÏ¿© ÁÖÀ§ Á¶Á÷À» ÆÄ±«, ħ½ÄÇÑ´Ù. ¶Ç ¾î¶² È­Çй°ÁúÀ» ³»¾î ÁÖÀ§ÀÇ Á¶Á÷ ¼¼Æ÷¸¦ Ä§ÇØÇÒ »Ó¸¸ ¾Æ´Ï¶ó, Ç÷°ü ¹× ¸²ÇÁ°üÀ» µû¶ó ÀüÀÌÇÏ¿© Àü½ÅÀÇ ¾Ç¾×ÁúÀ» ¾ß±â½ÃÄÑ Á×À½ÀÇ À§ÇèÀ» ÃÊ·¡ÇÑ´Ù. »óÇǼºÀÎ °ÍÀ» ¾ÏÁ¾À̶ó Çϰí, ºñ»óÇǼºÀÎ °ÍÀ» À°Á¾À̶ó ÇÑ´Ù.
  • nonodontogenic malignant tumor jaw
    ºñÄ¡¾Æ¼º ¾Ç¼º Á¾¾ç
  • ulcerated malignant tumor
    ±Ë¾ç¼º ¾Ç¼º Á¾¾ç
  • Castellani-Low symptom
    Ä«½ºÅÚ¶ó´Ï-·Î¿ì Áõ»ó
    ¼ö¸éº´ ȯÀÚ¿¡°Ô¼­ º¼ ¼ö ÀÖ´Â ¼³ ÁøÀü.
  • low
    ³·Àº, Àú
  • low birth weight
    ÀúüÁß Ãâ»ý
  • low carat gold alloy
    ÀúÄ«¶óÆ® ±Ý ÇÕ±Ý
    16Ä«¶óÆ® ÀÌÇÏÀÇ ±Ý ÇÕ±Ý. ³³Âø ÇÕ±ÝÀ» ¸»ÇÑ´Ù.
  • low copper amalgam
    Àú µ¿ ¾Æ¸»°¨
  • low frequency
    ÀúÁÖÆÄ
    Á֯ļö°¡ ³·Àº ÆÄ. Áï, ÀüÀÚ±âÆÄÀÇ Á֯ļö¿¡ ÀÇÇÑ ºÐ·ù·Î¼­, º¸Åë 10 kHz ÀÌÇϸ¦ ¸»ÇÑ´Ù. ¿Àµð¿À
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
low malignant potential tumour A neoplasm of the ovary, usually arising in young women, composed of complex epithelial hyperplasia without stromas invasion; may recur if incompletely removed surgically, but is clinically less aggressive than carcinoma.
Synonym: low malignant potential tumour.
(05 Mar 2000)
tumor 1. <oncology> An abnormal mass of tissue that results from excessive cell division that is uncontrolled and progressive, also called a neoplasm. Tumours perform no useful body function. They may be either benign (not cancerous) or malignant.
2. Swelling, one of the cardinal signs of inflammations, morbid enlargement.
Origin: L. Tumere = to swell
(12 May 1997)
tumor marker <investigation, oncology> A substance in the body that usually indicates the presence of cancer.
These markers are usually specific to certain types of cancer and are usually found in the blood or other tissue samples.
Examples are alphafetoprotein (AFP), human chorionic gonadotropin, and lactate dehydrogenase (LDH).
They may be indicators of tumour stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
(18 Jul 2002)
tumor necrosis factor <cytokine> Originally described as a tumour inhibiting factor in the blood of animals exposed to bacterial lipopolysaccharide or Bacille Calmette-Guerin.
Preferentially kills tumour cells in vivo and in vitro, causes necrosis of certain transplanted tumours in mice and inhibits experimental metastases. Human Tumour Necrosis factor alpha is a protein of 157 amino acids and has a wide range of pro inflammatory actions. Usually considered a cytokine.
Synonym: cachectin.
Acronym: TNF
(13 Nov 1997)
back pain, low Symptoms in the low back can relate to the bony lumbar spine, discs between the vertebrae, ligaments around the spine and discs, spinal cord and nerves, muscles of the low back, internal organs of the pelvis and abdomen, and the skin covering the lumbar area. The low back, or lumbar area, functions in structural support, movement, and protection of certain body tissue.
(12 Dec 1998)
blood sugar, low The sugar here is glucose. Low blood glucose constitutes hypoglycaemia. Hypoglycaemia is only significant when it is associated with symptoms. It has many causes including drugs, liver disease, surgical absence of the stomach, pre-diabetes, and rare tumours that release excess insulin.
(12 Dec 1998)
cardiac output, low A state of subnormal or depressed cardiac output, usually seen in patients with heart failure secondary to coronary artery, hypertensive, primary myocardial, valvular, or pericardial disease.
(12 Dec 1998)
very low density lipoprotein <biochemistry> A lipoprotein substances (combination of a fat and a protein) which acts as a carrier for cholesterol and fats (particularly triglycerides) in the bloodstream.
Elevations in very low density lipoprotein in the bloodstream are associated with an increased risk of atherosclerosis and coronary artery disease.
Acronym: VLDL
(18 Nov 1997)
Castellani-Low sign <clinical sign> A fine tremor of the tongue observed in sleeping sickness.
(05 Mar 2000)
mean lower low water <marine biology> The average height of the lower low waters over a 19-year period. For shorter periods of observations, corrections are applied to eliminate known variations and reduce the result to the equivalent of a mean 19-year value.
(09 Oct 1997)
mean low water <marine biology> The average height of the low waters over a 19-year period. For shorter periods of observations, corrections are applied to eliminate known variations and reduce the result to the equivalent of a mean 19-year value.
All low-water heights are included in the average where the type of tide is either semidiurnal or mixed. Only the lower low-water heights are included in the average where the type of tide is diurnal. So determined, mean low water in the latter case is the same as mean lower low water.
(09 Oct 1997)
placenta, low Location of the placenta in the lower part of the uterus (womb) so that the placenta partially or completely covers the cervix. Also known as a placenta previa.
(12 Dec 1998)
heparin, low-molecular-weight <chemical> Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of haemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism.
Pharmacological action: anticoagulant, fibrinolytic agent.
(12 Dec 1998)
infant, low birth weight An infant having a birth weight of 2500 gm. (5.5 lb.) or less but infant, very low birth weight is available for infants having a birth weight of 1500 grams (3.3 lb.) or less.
(12 Dec 1998)
infant, very low birth weight An infant having a birth weight of 1500 grams (3.3 lb.) or less.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • tumor
    Á¾±â
  • tumor
    Á¾Ã¢;ºÎ±â;Á¾±â
  • malignant
    ¾ÇÀǸ¦ ǰÀº; ¾Ç¼ºÀÇ; ¹ÝÇ×ÀÚ
  • malignant
    À¯ÇØÇÑ;¾Ç¼ºÀÇ;¾ÇÀǸ¦ ǰÀº;... (¿µ»ç) Charles I ½Ã´ëÀÇ ¿Õ´ç¿ø
  • malignant melanoma
    ¾Ç¼º Èæ»öÁ¾
  • potential
    ÀáÀçÇÏ´Â
  • contact potential
    Á¢ÃË ÀüÀ§Â÷
  • electric potential
    ˟ˤ
  • magnetic potential
    ÀÚÀ§
  • market potential
    ½ÃÀåÀÇ ÀáÀç ´É·Â
  • potential
    °¡´ÉÇÑ;°¡´É¼º;ÀüÀ§ÀÇ;°¡´É¹ýÀÇ;°¡´É¼º;Àá¼¼;ÀáÀç·Â;ÀüÀ§;°¡´É¹ý 1
  • potential sovereighty
    ÀáÀç ÁÖ±Ç
  • potential transformer
    °è±â¿ëº¯¾Ð±â
  • low
    ³·Àº,³·°Ô,õÇϰÔ,(¼Ò°¡)¿ï´Ù
  • low-minded
    ºñ¿­ÇÑ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á